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Summary: Ov16–Wb123 seroprevalence was measured in children ≤10 year-old to evaluate 
onchocerciasis and lymphatic filariasis elimination in two co-endemic foci (Bakoye and 
Falémé) in Mali under long-term ivermectin treatment, which stopped in 2016. These goals 
seem to have been achieved.  D
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Abstract 
 
Background. In Mali, ivermectin-based onchocerciasis elimination from the Bakoye and 
Falémé foci, reported in 2009–2012, was a beacon leading to policy shifting from morbidity 
control to elimination of transmission (EOT). These foci are also endemic for lymphatic 
filariasis (LF). In 2007–2016 mass ivermectin plus albendazole administration was 
implemented. We report Ov16 (onchocerciasis) and Wb123 (LF) seroprevalence after 24–25 
years of treatment to evaluate if onchocerciasis EOT and LF elimination as a public health 
problem (EPHP) have been achieved. 
Methods. The SD Bioline Onchocerciasis/LF IgG4 biplex rapid diagnostic test (RDT) was 
used in 2,186 children aged 3–10 years in 13 villages (plus two hamlets) in Bakoye, and 
2,270 children in 15 villages (plus one hamlet) in Falémé. In Bakoye, all-age serosurveys 
were conducted in three historically hyperendemic villages, testing 1,867 individuals aged 3–
78 years. 
Results. In Bakoye, IgG4 seropositivity was 0.27% (95%CI=0.13–0.60%) for both Ov16 and 
Wb123 antigens. In Falémé, Ov16 and Wb123 seroprevalence was, respectively, 0.04% 
(95%CI=0.01–0.25%) and 0.09% (95%CI=0.02–0.32%). Ov16-seropositive children were 
from historically meso- and hyperendemic villages. Ov16 positivity was <2% in those ≤14 
years, increasing to 16% in those ≥40 years. Wb123 seropositivity was <2% in those ≤39 
years, reaching 3% in those ≥40 years.  
Conclusions. Notwithstanding uncertainty in the biplex RDT sensitivity, Ov16 and Wb123 
seroprevalence among children in Bakoye and Falémé appears consistent with EOT 
(onchocerciasis) and EPHP (LF) since stopping treatment in 2016. The few Ov16-
seropositive children should be skin-snip PCR tested and followed up. 
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Abbreviations 
APOC: African Programme for Onchocerciasis Control; CDTI: community-directed treatment 
with ivermectin; CFA: circulating filarial antigen; CMFL: community microfilarial load; ELISA: 
enzyme-linked immunosorbent assay; EOT: elimination of transmission; EPHP: elimination 
as a public health problem; FMPOS: Faculty of Medicine, Pharmacy and 
Odontostomatology; FTS: filariasis test strip; GPELF: Global Programme to Eliminate 
Lymphatic Filariasis; ICT: immunochromatographic card test; IgG4: immunoglobulin G4; LF: 
lymphatic filariasis; MDA: mass drug administration; mf: microfilarial; mff: microfilariae; OCP: 
Onchocerciasis Control Programme in West Africa; PCR: polymerase chain reaction; RDT: 
rapid diagnostic test; spp: species; ss: skin snip; TAS: transmission assessment survey; 
USTTB: University of Sciences, Techniques and Technologies of Bamako; WHO: World 
Health Organization; 95% CI: ninety five percent confidence interval. 
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Onchocerciasis and lymphatic filariasis (LF) are endemic in Mali [1] but large-scale 
interventions have progressed towards elimination of transmission (EOT) for onchocerciasis 
and elimination as a public health problem (EPHP) for LF. The Onchocerciasis Control 
Programme in West Africa (OCP) began vector control in Mali in 1977, identifying and 
larviciding Simulium (blackfly) breeding sites [2]. Some endemic parts of Mali were included 
in the OCP western extension, with ivermectin mass drug administration (MDA) starting in 
1987. MDA was initially delivered by mobile teams and later by community-directed 
treatment with ivermectin (CDTI) assisted by the African Programme for Onchocerciasis 
Control (APOC) [3]. The Global Programme to Eliminate Lymphatic Filariasis (GPELF) 
started in Mali in 2004, supporting ivermectin and albendazole distribution [1]. 
In 2010, APOC launched a conceptual and operational framework for onchocerciasis 
elimination with ivermectin treatment [4], spurred by promising findings in foci of Mali and 
Senegal using this strategy. In 2012, following the World Health Organization (WHO) 
roadmap on neglected tropical diseases [5], the target for onchocerciasis changed from 
morbidity control to EOT, contrasting with the LF goal of EPHP [6].  
Mali became one of the first African countries to demonstrate the principle of onchocerciasis 
elimination by ivermectin MDA as the sole intervention when elimination was documented in 
the Bakoye and Falémé foci, in 2009 and 2012 [7,8], following 15 (Bakoye) and 16 (Falémé) 
years of annual treatment. Treatment duration corresponds to first–last year when all first-
line villages were treated, 1992–2006 (Bakoye) and 1991–2006 (Falémé) [7]. Because the 
LF programme started in 2007 in the same river basins, ivermectin distribution continued de 
facto for 9 years after 2006 (LF MDA stopped in 2016), bringing treatment duration to 24–25 
years. Since 2011, a bednet distribution programme for malaria (which would also impact 
Anopheles-transmitted LF [9], the type occurring in Mali) was implemented.  
For onchocerciasis, a threshold of <0.1% seropositivity (by IgG4 ELISA) to the Onchocerca 
volvulus Ov16 antigen in children aged <10 years is currently recommended by the WHO for 
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stopping ivermectin MDA [10]. For Anopheles-transmitted LF, the WHO guidelines 
recommend a threshold of <2% seropositivity to Wuchereria bancrofti circulating filarial 
antigen (CFA) with the filariasis test strip (FTS) (which replaced the immunochromatographic 
card test, ICT) in 6–7-year olds before ivermectin plus albendazole MDA may be stopped 
[11]. 
LF transmission assessment surveys (TAS) were conducted in 2016 and treatment stopped 
because all the health districts of the two foci passed the TAS using FTS, i.e. W. bancrofti 
antigenemia prevalence after 9 years of treatment was <2% at health district level [12], 
where sampling followed a community-based (household) design according to the WHO 
TAS protocol [11]. 
Documenting onchocerciasis elimination in Bakoye and Falémé was based on skin snip 
microscopy for detection and quantification of O. volvulus microfilaridermia, and PCR-based 
pool screening of blackfly samples for detection of infective, L3 larvae [7,8]. These data, 
alongside historical infection trends and treatment coverage information were later modelled 
using EPIONCHO and ONCHOSIM to estimate the risk of resurgence in Bakoye and the 
neighbouring River Gambia focus in Senegal [13] (data from Falémé were not available). 
Both models captured adequately the temporal prevalence trends and suggested a very low 
risk of resurgence in Bakoye, although EPIONCHO indicated a more substantive risk, 
particularly in historically hyperendemic communities [13]. Since the publication in 2016 of 
the World Health Organization (WHO) guidelines for stopping MDA and verifying 
onchocerciasis elimination [10], serological evaluation has become an important tool for 
transmission assessment.  
Here, we use a rapid diagnostic test [14,15] to assess onchocerciasis and LF 
seroprevalence in the Bakoye and Falémé foci, 10 years after the first evidence of 
onchocerciasis elimination in these foci [7] and 3 years after passing TAS for LF in an 
onchocerciasis–LF co-endemic area in Mali.  
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METHODS 
Ethical Approval 
The study protocol (no. 2017/199/CE/FMPOS) was approved by the Ethical Committee of 
the University of Sciences, Techniques and Technologies of Bamako (USTTB), Faculty of 
Medicine, Pharmacy and Odontostomatology (FMPOS). The objectives, procedure and 
methodology were explained to village elders and residents, and informed consent was 
obtained from parents/guardians of children and participants aged ≥18 years. 
Study Sites and Baseline Infection Indicators 
The study was conducted between November 2017 and January 2018 in the Bakoye and 
Falémé former onchocerciasis foci [7,8]. In Bakoye, 13 villages (plus two hamlets) were 
studied, which had had a baseline O. volvulus microfilarial (mf) prevalence of 31%–70%. In 
Falémé, 15 villages (plus one hamlet) were studied, whose baseline mf prevalence had been 
20%–57%. Figure 1 shows the locations of the foci and study villages in Mali. Tables 1 and 2 
summarize, for Bakoye and Falémé respectively, pre-control parasitological data (mf 
prevalence and community microfilarial load (CMFL)). LF was endemic in the health district 
of Kita (Bakoye) and Kéniéba (Falémé) with a baseline antigenemia prevalence (in those 
≥15 years) of 8.61% (13/151; 95% CI = 5.1–14.2%) using ICT to detect CFA in 2004 [12]. 
Supplementary Material provides further description of the study sites and onchocerciasis 
temporal trends under MDA. 
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Figure 1 
Table 1, Table 2 
Study Populations 
Serum samples were collected from children aged 3‒10 years borne/resident in Bakoye and 
Falémé in December 2017. In January 2018, and because modelling [13] had suggested a 
potential risk of resurgence in previously hyperendemic villages in Bakoye, serosurveys 
were also performed in the remaining (long-term resident) population (aged 11–78 years) in 
Kantila, Nioumala and Galé, which had had mf prevalences above 60% (Table 1). This was 
deemed not necessary in villages of lower baseline endemicity in both the Bakoye and 
Falémé foci. 
Serology Test 
The SD Bioline Onchocerciasis/LF IgG4 biplex rapid diagnostic test (RDT) [14,15] was used 
at the point-of-care as recommended by the manufacturer (SD Diagnostics, Korea). The test 
result was read after 30 minutes.  
Sample Sizes 
Sample sizes were calculated based on updated census data obtained in 2016–2017, 
provided by the Kita and Kéniéba health districts. It was estimated that the 3‒10-year olds 
comprised approximately 22% of the population based on empirical data from 
onchocerciasis-endemic communities in Africa used to inform EPIONCHO’s demographic 
structure [19], in agreement with the OCP reference population [16]. The proportional 
representation of different age groups in the three historically hyperendemic communities in 
the Bakoye focus was calculated in an analogous manner. 
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The study was powered on the basis of our a priori expectation that onchocerciasis EOT had 
taken place in Bakoye and Falémé since the last rounds of CDTI for onchocerciasis were 
undertaken in 2006‒2007 [7,8] and for a further 9 years for LF. Therefore, the ‘true’ 
underlying seroprevalence in 3‒10-year olds would be 0%. We further assumed that the 
specificity of the RDT was approximately 97.5% [14,15] and, therefore, we calculated 
sample sizes required to measure an RDT seroprevalence of 2.5% with a +/-0.5% precision. 
This yielded, for the first phase of the study, sample sizes of 3,508 in Bakoye and of 2,739 in 
Falémé. According to [10], a sample size of 2,000 children is needed to detect an Ov16 
seroprevalence <0.1% (upper 95% confidence limit). 
For the second phase (all-age serosurvey) of the study, sample sizes for all other age 
groups (≥11 years) in the three selected historically hyperendemic communities in Bakoye 
were based on estimating 50% seroprevalence (by RDT) with a precision of +/-5%. The 
value of 50% provided the most conservative sample size estimate of 1,257. In all cases, 
sample size calculations included a finite population size correction (i.e. sampling without 
replacement). 
Data Analysis 
The standardized mf prevalence at baseline reported in Tables 1 and 2 are accompanied by 
95% confidence intervals (95% CIs) calculated according to Wilson score interval [17]. Point 
seroprevalence estimates and associated 95% CIs were calculated using the same method 
by focus, village, and age group. 
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RESULTS 
Study Population Characteristics 
In the Bakoye focus, 2,186 children (aged 3–10 years were tested for Ov16 and Wb123 
IgG4 positivity (62% of the target sample size). The median age was 7 years and 53.6% 
were boys. For the three villages in which all-age serological surveys were conducted, 825 
individuals aged ≤10 years and 1,042 individuals (aged ≥11 years) were tested (93% of the 
target); of the latter, the median age was 19 years, and 47.6% were men. In the Falémé 
focus, 2,270 children aged 3–10 years were included in the study (83% of the target). 
Village-level sample sizes for Bakoye and Falémé are given in Supplementary Material, 
Table S1. The median age was 6 years, and 51.9% were boys. Table 3 describes the 
population tested. 
Table 3 
Onchocerciasis Mf Prevalence and CMFL Trends in Bakoye and Falémé 
Figures 2 and 3 depict the decrease in mf prevalence and CMFL for the two foci, 
respectively, during 15–16 years of annual ivermectin MDA [7]. In Bakoye, levels of initial 
endemicity were higher than in Falémé. By 2010 (the last skin snip-based parasitological 
evaluation following the last ivermectin MDA round for onchocerciasis in 2006), most 
reported values were zero in both foci, with 95% CIs reflecting uncertainty due to sampling. 
Figure 2, Figure 3 
Ov16 and Wb123 Seroprevalence Among Children in Bakoye and Falémé 
In Bakoye, 6/2,186 children aged 3–10 years were positive for Ov16 IgG4 (0.27%, 95% CI = 
0.13–0.60%), and 6 children were also positive for Wb123 IgG4 antibodies (same 
prevalence and 95% CIs but not necessarily the same children). The children who were 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciaa318/5811165 by guest on 30 M
arch 2020
12 
 
12 
 
Ov16-positive were from the initially mesoendemic village of Badougou (a girl aged 10 
years), the hyperendemic village of Kibi (a boy, aged 10, who was also positive for Wb123), 
and the highly hyperendemic village of Galé, where four children were seropositive (one girl 
aged 4 and another aged 8, positive for Ov16 only, plus one boy aged 7 and a girl aged 10, 
positive for both Ov16 and Wb123). The children who were only positive for Wb123 came 
from the villages of Kokounkoutouba (a boy aged 3), Kantila (a girl aged 9), and Galé (a boy 
aged 4). Supplementary Material, Table S1 presents Ov16 and Wb123 seropositivity per 
village in Bakoye. 
In Falémé, Ov16 positivity was 1/2,270 (0.04%, 95%CI = 0.01–0.25%) in the 3–10-year-olds, 
the positive child originating from the mesoendemic community of Sely (one boy aged 7). 
Wb123 seropositivity was 2/2,270 (0.09%, 95%CI = 0.02–0.32%), the positive children being 
from the villages of Madina-Mandinga (a girl aged 7) and Mahinamine (a boy aged 10). 
Supplementary Material, Table S2 presents Ov16 and Wb123 seropositivity per village in 
Falémé. 
Age-Specific Seroprevalence of Ov16 and Wb123 in Bakoye 
In the 3 historically hyperendemic villages selected for full age-range serological sampling, 
Ov16 IgG4 antibodies were detected in all 3 villages. Overall seroprevalence estimates (for 
individuals aged 3–78 years) were: 0.63% (95% CI = 0.17–2.26%) in Kantila (2 positives/319 
tested); 7.0% (95% CI = 4.22–11.41%) in Nioumala (14 positives/200 tested), and 2.97% 
(95% CI = 2.19–4.02%) in Galé (40 positives/1,348 tested). 
Wb123 IgG4 antibodies were also detected in all 3 villages. Overall seroprevalence 
estimates (for individuals aged 3–78 years) were: 0.31% (95% CI = 0.06–1.75%) in Kantila 
(1 positive/319 tested); 1.0% (95% CI = 0.27–3.57%) in Nioumala (2 positives/200 tested), 
and 1.19% (95% CI = 0.73–1.92%) in Galé (16 positives/1,348 tested). Figure 4 presents the 
age profiles of Ov16 and Wb123 seropositivity in the three villages combined. 
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Supplementary Material, Table S3 presents the results of Ov16 and Wb123 serology by age 
group in each of the three villages. 
Figure 4 
DISCUSSION 
The proof-of-principle onchocerciasis elimination from the Bakoye, Falémé and River 
Gambia foci in Mali and Senegal [7,8] provided seminal evidence that elimination in Africa 
could be achieved using ivermectin alone. This was pivotal in driving change in the 
WHO/APOC onchocerciasis goals from control to elimination [4]. Elimination was assessed 
based on epidemiological (skin snipping to detect/enumerate microfilariae) and 
entomological (PCR to detect O. volvulus L3 larvae in blackflies) evidence [7,8]. Since 2016, 
the WHO has advocated more stringent serological criteria for the safe stopping of MDA. 
These include the (statistically significant) demonstration of an Ov16 (by IgG4 ELISA) 
seroprevalence of <0.1% in children aged <10 years as measured [10]. For bancroftian 
(Anopheles-transmitted) LF, the FTS test is recommended for TAS and post-elimination 
surveillance, with a threshold of <2% [11]. The serological data presented here were 
obtained using the SD Bioline Onchocerciasis/LF IgG4 RDT test and so cannot be used for 
direct comparison with recommended thresholds indicative of elimination. However, these 
data do provide important empirical information on filariases transmission status in Mali. 
Robust interpretation of serological data critically depends on the assay’s diagnostic 
performance. The SD Bioline biplex test has a (manufacturer)-reported sensitivity of 92–98% 
for onchocerciasis and 81–95% for LF. Specificity estimates are, respectively, 97–100% and 
96–99% [20]. Notwithstanding uncertainty in the field performance of the biplex RDT 
[14,15,21]—and the need for field-based studies to confirm the utility of the test for 
verification of elimination [22,23]—the Ov16 seroprevalence of 0.27% and 0.04% in children 
aged 3–10 years in, respectively, Bakoye and Falémé is broadly consistent with EOT. The 
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Wb123 seroprevalence of 0.27% in Bakoye and 0.09% in Falémé is also likely consistent 
with EPHP for LF, although there is no operational guidance on the interpretation of Wb123 
serology in the context of LF transmission (but see [21]). Therefore, at the focus level and as 
of 2017–2018, we find no substantive evidence of onchocerciasis or LF resurgence since 
MDA cessation in 2016. However, the few Ov16 seropositive children identified here should 
be PCR-tested on skin snips to distinguish between parasite exposure and infection; if found 
negative, they could be omitted from the seroprevalence calculation but re-examined 1–1.5 
years later to determine if they have become patent and should be treated [10]. 
The serological results in Bakoye contribute to validate previous modelling projections, 
indicating sustained elimination when EPIONCHO was fitted to the entire longitudinal data 
series (Fig. 3c of [13]). By contrast, likely resurgence was predicted by EPIONCHO (but not 
ONCHOSIM) in the neighbouring and more highly endemic River Gambia focus in Senegal 
(which was treated biannually) (Fig. 3g of [13]). Indeed, ivermectin MDA was resumed by the 
Senegalese National Onchocerciasis Control Program in the River Gambia focus in 2013 
[24]. In 2014, an Ov16/Wb123 serological evaluation (using Luminex® multiplex-bead 
assay) across three river basins of the Kédougou Region (containing areas and some 
communities of [7,8]), found an Ov16 seroprevalence of 2.5% (7/279) in <10-year olds, 
including three positives in the River Gambia focus and four positives in the Senegalese part 
of the Falémé focus [24]. It is unclear whether these children were found in the same 
communities previously reported free of onchocerciasis transmission [7,8], but concerns 
were raised that transmission had either not been interrupted or had resurged [24]. All-age 
Ov16 serological profiles in the Bakoye focus of Mali [this work] are compared with those of 
the Kédougou Region of Senegal [24] in Supplementary Material Figure S1. Resurgence of 
onchocerciasis has been reported elsewhere in West Africa [25,26] highlighting the 
importance of robust epidemiological and entomological surveillance following cessation of 
interventions [27]. 
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The three villages in Bakoye and one in Falémé that had children aged ≤10 years who were 
Ov16 IgG4 antibody positive were meso- or hyperendemic at baseline. The village of Galé—
one of the largest and most hyperendemic villages before MDA (Figure 2)—had four 
seropositive (out of six in Bakoye) children (0.6%, Supplementary Material, Table S1). 
Although, arguably, these may all be false positives, variation in seropositivity among 
villages highlights the importance of spatial scale when designing monitoring, evaluation and 
surveillance sampling protocols. There currently exists no explicit guidance on how 
onchocerciasis elimination surveys should be implemented, nor on the appropriate spatial 
unit. For LF, an online survey-design tool can be used for school-based or community-based 
cluster randomised surveys within ‘evaluation units’ [11]. More guidance is needed on how 
best to implement onchocerciasis serological (and entomological) surveys. Spatially-explicit 
protocols, which have been developed for onchocerciasis elimination mapping (to identify 
previously untreated hypoendemic areas) [21] may prove useful.  
The certainty of evidence indicative of onchocerciasis elimination for the <0.1% serological 
threshold in children aged <10 years is low [10]. Recent modelling work has suggested that 
a higher threshold of 2% may be safe for stopping MDA and that children aged 5–14 years 
may be more informative [28]. Yet, considerable uncertainty remains on both the technical 
threshold for elimination—which is confounded by limited understanding of O. volvulus 
transmission dynamics and population biology at low transmission levels [29]—and whether 
a particular threshold can be measured using current diagnostic tools [30], particularly RDTs 
[21,22]. The WHO currently recommends Ov16 ELISA serology, but different ELISA 
protocols vary in performance characteristics, and laboratory capacity in Africa must be 
strengthened [31,32]. The development and manufacture of standardized and quality-
assured ELISA kits with sensitivity/specificity compatible with measuring (revised) 
serological thresholds is a priority. 
Inspection of all-age serological profiles in the previously hyperendemic villages of Kantila, 
Nioumala and Galé analysed together provides an overview of historical exposure trends in 
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Bakoye. Seroprevalence was very low in the ≤14-year olds, with upper 95% confidence 
limits less than 2% in 3–6, 7–10 and 11–14 (Figure 4), suggesting pronounced transmission 
suppression. Despite the majority of young adults in the 15–19 and 20–24 age groups having 
lived their lives under MDA with ivermectin, the Ov16 seroprevalence of between 
approximately 3% and 5% indicates some exposure to O. volvulus, probably before the 
interruption of transmission (i.e. not necessarily indicative of current transmission). From 15–
19, Ov16 seroprevalence increases slowly with age, only reaching 16% in those aged ≥40 
years. These individuals would have been ≥15–20 years old when ivermectin distribution 
began and, under intense pre-treatment transmission, their age-specific mf prevalence 
would already have reached >60% [33]. These results are consistent with those of [34], 
indicating that Ov16 seropositivity likely declines over time after prolonged treatment 
(although mortality rates in these populations would have also to be considered). 
The all-age seroprevalence profiles for Wb123 also increased somewhat with age, reaching 
3% in those aged ≥40 years but remaining below 2% in all those aged <40. A recent study in 
Mali found a strong correlation between ICT and Wb123 seropositivity in children aged 6–7 
years, suggesting that evaluating IgG4 to Wb123 might in the future (pending further 
(sero)epidemiological investigations) be useful in stop-MDA decisions or in TAS following 
MDA cessation, as a measure of recent exposure rather than patent infection [35]. The study 
in Mali also reported Ov16 seropositivity in children from previously onchocerciasis meso- 
and hyperendemic communities and none from hypoendemic villages. These findings, 
together with those presented here and reported in Senegal for children aged <10 years, 
where the seven seropositive individuals were found in the River Gambia and Fálémé foci 
[24], indicate that not all Ov16-seropositive results should be dismissed as false positives, as 
a trend is clearly emerging associating Ov16 seropositivity with pre-MDA endemicity status. 
It is hoped that current LF antigenemia and mf prevalence thresholds for EPHP will be 
sufficient to lead to EOT, albeit empirical evidence for this is limited [23] and LF may persist 
despite passing TAS [36]. In reality, thresholds indicative of interrupted transmission will vary 
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with transmission conditions and local vector biting rates [37]. Hence, while mathematical 
modelling [28,37] can help decision-makers define thresholds based on acceptable levels of 
risk, elimination will ultimately be demonstrated using robustly-sampled surveillance data. 
Surveillance will come at a cost that the global health community must recognise and 
prepare for to sustain the great progress already been made along the path to eliminating 
onchocerciasis and LF. 
CONCLUSIONS 
The antibody seroprevalence against Ov16 and Wb123 antigens among children in the 
Bakoye and Falémé foci in Mali is very low and consistent with both onchocerciasis and LF 
having been likely eliminated since stopping MDA in 2016 (pending skin snip PCR-testing of 
the few Ov16 seropositive children identified, and with the proviso that new studies are 
needed to confirm the field performance of the biplex RDT). Periodic (including 
entomological) surveillance should be continued in this region to detect and respond to any 
early signs of resurgence/re-introduction. This will help to sustain elimination and maintain 
the Bakoye and Falémé foci as an example of a global health intervention success. 
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Table 1. Prevalence and Intensity of Onchocerca volvulus Microfilariae in the Pre-
Ivermectin MDA Period (1985–1988) for 13 Villages in Bakoye, Mali 
 
Village Year 
of 
survey 
Census 
(% 
exam) 
Positive/ 
examined 
Prevalence 
(%)a 
(95% CI)b 
CMFL 
(mff/ss)c 
Endemicity 
leveld 
Fataba-
Kouroubala 
1988 284 
(75.4) 
57/ 
214 
30.6 
(24.5–36.7) 
3.22 Hypoendemic 
Kokounkoutouba 1987 173 
(70.5) 
28/ 
122 
30.7 
(22.6–38.8)  
2.29 Hypoendemic 
Baniangafata 1988 208 
(75.5) 
57/ 
157 
39.7 
(32.1–47.3) 
4.36 Hypoendemic 
Dianga-Foula 1985 214 
(47.2) 
48/ 
101 
43.5 
(34.1–53.3) 
16.91 Mesoendemic 
Fatafing  1987 335 
(78.5) 
106/ 
263 
45.5 
(39.7–51.7) 
6.17 Mesoendemic 
Badougou  1988 160 
(68.1) 
45/ 
109 
48.4 
(39.4–58.0) 
4.37 Mesoendemic 
Tieourou-
Santankoto 
1988 340 
(86.2) 
142/ 
293 
48.6 
(42.8–54.2) 
10.20 Mesoendemic 
Madila 1987 204 
(83.3) 
82/ 
170 
50.1 
(42.5–57.5) 
8.17 Mesoendemic 
Kantila  1985 171 
(83.6) 
84/ 
143 
60.1 
(52.0–67.9) 
17.25 Hyperendemic 
Keniefeto 1988 127 
(78.0) 
51/ 
99 
62.4 
(52.9–71.7) 
14.92 Hyperendemic 
Nioumala 1985 98 
(72.5) 
52/ 
71 
64.9 
(53.3–75.2) 
33.94 Hyperendemic 
Kibi 1988 205 
(72.2) 
90/ 
148 
67.5 
(59.8–74.8) 
21.62 Hyperendemic 
Galé  1985 410 
(62.9) 
173/ 
258 
70.0 
(64.4–75.5) 
31.13 Hyperendemic 
a
Standardised prevalence according to OCP reference population [16]; 
b
Wilson 95% confidence intervals [17]; 
c
CMFL: geometric mean no. of microfilariae (mff) per skin snip (ss) in those aged ≥20 years according to Remme 
et al. [18]; 
d
endemicity levels are defined as: hypoendemic = microfilarial (mf) prevalence <40%; mesoendemic = 
mf prevalence ≥40% but <60%, and hyperendemic = mf prevalence ≥60% following [13].  
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Table 2. Prevalence and Intensity of Onchocerca volvulus Microfilariae in the Pre-
Ivermectin MDA Period (1986–1990) for 14 Villages in Falémé, Mali 
 
Village Year 
of 
survey 
Census 
(% 
exam) 
Positive/ 
examined 
Prevalence 
(%)a 
(95% CI)b 
CMFL 
(mff/ss)c 
Endemicity 
leveld 
Madina-
Mandinga 
1990 414 
(81.9) 
53/ 
339 
19.9 
(15.9–24.3) 
2.30 Hypoendemic 
Koffing 1987 244 
(84.4) 
46/ 
206 
23.3 
(18.1–29.5) 
1.55 Hypoendemic 
Yatia-Berola 1986 217 
(81.6) 
45/ 
177 
24.3 
(18.6–31.1) 
1.29 Hypoendemic 
Sakola-Loulo 1986 343 
(70.3) 
52/ 
241 
26.6 
(21.4–32.5) 
1.68 Hypoendemic 
Djoulafoundouni 1986 220 
(74.6) 
43/ 
164 
30.3 
(24.0–37.9) 
2.88 Hypoendemic 
Koutila 1986 227 
(77.1) 
55/ 
175 
33.0 
(26.6–40.4) 
5.37 Hypoendemic 
Djidian-Kenieba 1986 133 
(89.5) 
48/ 
119 
40.1 
(32.0–49.3) 
6.23 Mesoendemic 
Moussala 1989 214 
(80.4) 
65/ 
172 
42.2 
(35.3–49.9) 
5.18 Mesoendemic 
Sanoukou 1986 164 
(82.9) 
55/ 
136 
42.2 
(34.0–50.3) 
5.18 Mesoendemic 
Satadougou-
Tintiba 
1986 170 
(82.4) 
55/ 
140 
43.3 
(35.6–51.9) 
4.36 Mesoendemic 
Sely 1986 231 
(71.4) 
61/ 
165 
43.5 
(36.3–51.3) 
6.20 Mesoendemic 
Fadougou 1986 200 
(76.0) 
65/ 
152 
47.5 
(39.6–55.3) 
6.41 Mesoendemic 
Kounda-Mahina 1986 271 
(80.1) 
72/ 
217 
47.7 
(41.4–54.6) 
7.02 Mesoendemic 
Mankouke 1986 290 
(74.8) 
125/ 
217 
56.8 
(50.0–63.1) 
20.93 Mesoendemic 
a
Standardised prevalence according to OCP reference population [16]; 
b
Wilson 95% confidence intervals [17]; 
c
CMFL: geometric mean no. of microfilariae (mff) per skin snip (ss) in those aged ≥20 years according to Remme 
et al. [18]; 
d
endemicity levels are as defined in Table 1 [13]. 
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Table 3. Description of the Study Population Tested with Onchocerciasis/LF IgG4 
Rapid Diagnostic Test in Bakoye and Falémé, Mali, 2017–2018 
 
  Bakoye  Falémé 
  N (% target) % or [range]  N (% target) % or [range] 
Age group   
Children aged ≤10 years  2,186 (62.3%) 
 
2,270 (82.9%) 
 
3–6 yr  1,003 45.9 1,415 62.3 
7–10 yr  1,183 54.1 855 37.7 
Median age (years) 7 [3–10]  6 [3–10] 
Male/ 
Female 
1,172/ 
1,014 
53.6/ 
46.4 
1,178/ 
1,092 
51.9/ 
48.1 
Children aged ≤10 years 
(Kantila, Nioumala, Galé) 
825 (110.4%)  – – 
Persons aged >10 years 
(Kantila, Nioumala, Galé) 
1,042 (82.9%) 
 
– – 
11–14 yr 309 (149.3%) 29.7 – – 
15–19 yr  232 (124.7%) 22.3 – – 
20–24 yr  114 (69.1%) 10.9 – – 
25–29 yr  70 (47.6%) 6.7 – – 
30–39 yr  134 (72.0%) 12.9 – – 
40–49 yr 71 (48.6%) 6.8 – – 
≥50 yr 112 (50.9%) 10.8 – – 
Median age (years) 19 [11–78] – – 
Male/ 
Female 
496/ 
546 
47.6/ 
52.4 
– – 
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Figure legends 
Figure 1. Map of the study area and the location of the study villages in the Kayes region 
of Mali. (A) Map of Mali showing the location of the Bakoye (solid contour) and Falémé (dashed 
contour) foci; inset indicates location of Mali within Africa. (B) The Bakoye focus is in the Kita 
cercle, with most the 15 study communities (13 villages and two hamlets) located along the 
Bakoye river. (C) The Falémé focus is in the Kéniéba cercle, with the 16 study communities (15 
villages and one hamlet) located along the Falémé river (bordering Senegal). Cercles are the 
second administrative unit in Mali (the first being regions). Villages (indicated by solid circles) 
are coloured by their baseline endemicity level: yellow (hypoendemic), orange (mesoendemic) 
and red (hyperendemic); green circles denote locations for which no baseline data (collected in 
1985–1989) were available and therefore their initial endemicity status is unknown. 
Figure 2. Trends in Onchocerca volvulus microfilarial infection in Bakoye from 1985 to 
2010. (A) Microfilarial (Mf) prevalence. (B) Community Microfilarial Load (CMFL), as defined in 
Table 1 [18]. Error bars for prevalence denote (Wilson score interval) 95% CIs [17]. The 
baseline data correspond to 1985–1989. In 1989 annual ivermectin MDA started with an initial 
coverage of 59–62% which improved to 73–83% in 1998–2006 [13]. From 1992 onwards, all 
first-line villages were treated [7]. 
Figure 3. Trends in Onchocerca volvulus microfilarial infection in Falémé from 1986 to 
2010. (A) Microfilarial (Mf) prevalence. (B) Community Microfilarial Load (CMFL), as defined in 
Table 1 [18]. Error bars for prevalence denote (Wilson score interval) 95% CIs [17]. The 
baseline data correspond to 1986–1990. In 1990 annual ivermectin MDA started with an initial 
coverage of 63% which improved to 75–82% in 2000–2006. From 1991 onwards all first-line 
villages were treated [7]. 
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Figure 4. Age-specific Ov16 and Wb123 seroprevalence profiles in the villages of Kantila, 
Nioumala and Galé combined. Ov16 (white bars) and Wb123 (grey bars) seropositivity by age 
group with 95% (Wilson score) confidence intervals. 
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